No connection

Search Results

ADTX vs LYRA

ADTX
Aditxt, Inc.
BEARISH
Price
$1.82
Market Cap
$0.4M
Sector
Healthcare
AI Confidence
95%
LYRA
Lyra Therapeutics, Inc.
BEARISH
Price
$0.65
Market Cap
$1.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ADTX
--
LYRA
--
Forward P/E
ADTX
-0.16
LYRA
-0.66
P/B Ratio
ADTX
-0.01
LYRA
-0.25
P/S Ratio
ADTX
67.96
LYRA
2.9
EV/EBITDA
ADTX
-0.22
LYRA
-0.53

Profitability

Gross Margin
ADTX
0.0%
LYRA
-152.76%
Operating Margin
ADTX
-419870.0%
LYRA
-98728.6%
Profit Margin
ADTX
0.0%
LYRA
0.0%
ROE
ADTX
--
LYRA
-6594.98%
ROA
ADTX
-61.7%
LYRA
-36.06%

Growth

Revenue Growth
ADTX
-89.1%
LYRA
-96.7%
Earnings Growth
ADTX
--
LYRA
--

Financial Health

Debt/Equity
ADTX
--
LYRA
--
Current Ratio
ADTX
0.02
LYRA
1.71
Quick Ratio
ADTX
0.02
LYRA
1.67

Dividends

Dividend Yield
ADTX
--
LYRA
--
Payout Ratio
ADTX
0.0%
LYRA
0.0%

AI Verdict

ADTX BEARISH

ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of an Altman Z-Score, which raises significant bankruptcy risk. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years. Despite a low price of $1.82, the valuation metrics are nonsensical (e.g., Price/Sales of 67.96, negative P/E), suggesting extreme overvaluation or data failure. The absence of any analyst coverage and negative insider activity further confirm a lack of institutional confidence.

Strengths
Minimal market cap may offer speculative appeal for high-risk investors
Recent quarter showed a slight Q/Q EPS improvement (+6.9%)
One quarter beat earnings estimate (1/4), indicating potential for volatility in results
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational efficiency
Negative ROA (-61.70%) and operating margin (-419,870.30%) signal severe profitability collapse
Revenue declined 89.10% YoY, with inconsistent and erratic earnings surprises (avg -96.38%)
LYRA BEARISH

LYRA is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.25, indicating negative shareholder equity. The company has experienced a catastrophic revenue collapse of -96.70% YoY and an extreme operating margin of -98,728.57%. With a 52-week high of $37.50 now trading at $0.65, the stock has lost nearly all its value. The combination of negative equity, vanishing revenue, and bearish insider activity suggests a high risk of insolvency.

Strengths
Current ratio of 1.71 suggests some remaining short-term liquidity
Quick ratio of 1.67 indicates liquidity is not heavily tied to inventory
Recent quarterly EPS losses are smaller in absolute terms than historical peaks
Risks
Extreme bankruptcy risk indicated by negative equity (P/B -0.25)
Catastrophic revenue decline of -96.70% YoY
Severe operational inefficiency with an operating margin of -98,728.57%

Compare Another Pair

ADTX vs LYRA: Head-to-Head Comparison

This page compares Aditxt, Inc. (ADTX) and Lyra Therapeutics, Inc. (LYRA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile